SYK
Stryker CorporationNYSEHealth CareMedical DevicesSnapshot 2026-05-08
As of May 8, 2026, SYK has a composite score of 10.8 and a signal label of "mild favorable." This score is influenced by a medium confidence level of 72.4 and a quality score of 76.2. Key drivers include macroeconomic factors such as labor, rates, growth, and inflation, with notable unfavorable scenarios related to potential guidance cuts and sector trends. The assessment is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.16
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $3.46 → $3.47 (+0.4% / 30d). 11 raised, 9 cut, 23 covering analysts.
0 upgrades, 0 downgrades / 30d, 11 maintained. 76% of analysts rate Buy.
9 PT revisions / 30d. Avg target 21.9% above current price.
0 positive, 2 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
6 material events in the last 24 months — top 5 listed below.
Stated priorities
2 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Maintain organic net sales growthgrowthbehind0% progress
4/30: “We are maintaining our full year 2026 guidance of organic net sales growth in the range of 8.0% to 9.5%.”
Why this status
Stated in 2 of last 2 quarters. Revenue was $5.273B in 2025-Q4, showing a decline from $6.057B in 2025-Q3. Despite maintaining guidance for 2026, the trajectory shows limited progress with revenue declining in the latest quarter.
- 2.Maintain adjusted EPS guidancegrowthbehind0% progress
4/30: “We are maintaining our full year 2026 guidance of adjusted net earnings per diluted share in the range of $14.90 to $15.10.”
Why this status
Stated in 2 of last 2 quarters. Net income was $462M in 2025-Q4, down from $859M in 2025-Q3. Despite maintaining EPS guidance for 2026, the trajectory shows limited progress with net income declining in the latest quarter.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 29%; 252d 21%.
Drawdown — Max 1y −29%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.69 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 65/100, drawdown 43/100, beta 69/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Maintain organic net sales growth
GrowthNew since 2026-05-04Stryker aims to maintain its organic net sales growth within the range of 8.0% to 9.5% for 2026.
BehindStated in 2 of last 2 quarters. Revenue was $5.273B in 2025-Q4, showing a decline from $6.057B in 2025-Q3. Despite maintaining guidance for 2026, the trajectory shows limited progress with revenue declining in the latest quarter.
0%CEO/CFO:“We are maintaining our full year 2026 guidance of organic net sales growth in the range of 8.0% to 9.5%.”Multiple sourcesSource dated 2026-04-30Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“We are maintaining our full year 2026 guidance of organic net sales growth in the range of 8.0% to 9.5%.”
- 2025-Q4Multiple sources
“we expect 2026 organic net sales growth to be in the range of 8.0% to 9.5%”
- #2
Maintain adjusted EPS guidance
GrowthNew since 2026-05-04Stryker aims to maintain its adjusted EPS guidance in the range of $14.90 to $15.10 for 2026.
BehindStated in 2 of last 2 quarters. Net income was $462M in 2025-Q4, down from $859M in 2025-Q3. Despite maintaining EPS guidance for 2026, the trajectory shows limited progress with net income declining in the latest quarter.
0%CEO/CFO:“We are maintaining our full year 2026 guidance of adjusted net earnings per diluted share in the range of $14.90 to $15.10.”Multiple sourcesSource dated 2026-04-30Stated 2 of last 8 quartersFirst seen 2026-05-04Show history (2)
- 2026-Q1Multiple sources
“We are maintaining our full year 2026 guidance of adjusted net earnings per diluted share in the range of $14.90 to $15.10.”
- 2025-Q4Multiple sources
“we expect adjusted net earnings per diluted share to be in the range of $14.90 to $15.10”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks more expensive than peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
SYK Stryker Corporation | +11 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently REAFFIRMED as of 2026-04-30)+4.0 pts
- If next-quarter guidance is cut (currently REAFFIRMED as of 2026-04-30)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-308d agoItem 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Stryker Corporation issued a press release on April 30, 2026 announcing its first quarter 2026 operating results. A copy of this press release is attached hereto as Exhibit 99.1. The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, a…
earnings preannouncementnegativescore 66 - 2026-04-0929d agoItem 7.01
of this Amendment, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Caution Concerning Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements subject to the safe harbor protection provided by…
legal regulatorynegativescore 26 - 2026-03-231mo agoItem 7.01
Regulation FD Disclosure. As previously reported in two separate Current Reports on Form 8-K, filed with and furnished to (as the case may be) the U.S. Securities and Exchange Commission (the “SEC”) on March 11, 2026, and March 12, 2026, respectively, Stryker Corporation (the “Company”) disclosed that the Company had identified a cybersecurity incident. Since then, the Company has worked around the clock, together with third-party experts and law enforcement to contain and neutralize the impa…
legal regulatorynegativescore 18 - 2026-03-121mo agoItem 7.01
Regulation FD Disclosure. As previously reported on March 11, 2026, Stryker Corporation (“we” or the “Company”) identified a cybersecurity incident affecting certain information technology systems of the Company that resulted in a global disruption to the Company’s Microsoft environment. On March 12, 2026, Dave Nathans, the Company’s Chief Information Security Officer, provided an update to certain of the Company’s customers and other members of the cybersecurity community regarding the ongoi…
legal regulatorynegativescore 14 - 2026-03-111mo agoItem 8.01
Other Events. On March 11, 2026, Stryker Corporation (“we” or the “Company”) identified a cybersecurity incident affecting certain information technology systems of the Company that has resulted in a global disruption to the Company’s Microsoft environment. Upon detection, the Company activated its cybersecurity response plan and launched an investigation internally with the support of external advisors and cybersecurity experts to assess and to contain the threat. The Company has no indicati…
legal regulatorynegativescore 14
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.